Fig. 3. RSV activates autophagic flux in PDGF-BB-stimulated in VSMCs.
Western blot analysis for LC3-I/II expression in (A) basal and (B) PDGF-BB-stimulated VSMCs. The cells were treated with RSV (10, 20 and 40 μM) or/and PDGF-BB (25 ng/ml) for 48 h. *p < 0.05 vs. No PDGF-BB-treated group, ##p < 0.01 and ####p < 0.0001 vs. PDGF-BB-treated group. (C) Representative immunostaining image for LC3 and PCNA on RSV and PDGF-BB-stimulated VSMCs. The cells were treated with RSV (40 μM) and PDGF-BB (25 ng/ml) for 48 h. Blue, DAPI; Green, LC3; Red, PCNA. Scale bar: 20 μm. (D) qPCR analysis for Beclin-1, Atg3, Atg5, and Atg7 mRNA expression. The cells were treated with RSV (40 μM) or/and PDGF-BB (25 ng/ml) for 48 h. *p < 0.05, ***p < 0.001, ****p < 0.0001. Data were analyzed using mean ± SEM. All experimental techniques are described in the Methods section. n = 3 per group. RSV, rosuvastatin; PDGF, platelet-derived growth factor; VSMCs, vascular smooth muscle cells; LC3, light chain 3; PCNA, proliferating cell nuclear antigen; DAPI, 4’,6-diamidino-2-phenylindole; qPCR, quantitative polymerase chain reaction; n.s., no significant.
© Korean J Physiol Pharmacol
